

PROVINCIAL FUNDING SUMMARY

Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia (pCODR 10105)

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: March 19, 2018

This information is current as of October 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Funded	Sep 1, 2019	<ul style="list-style-type: none"> Relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with or without chromosome 17p deletion, who have progressed on or are intolerant to B-cell receptor pathway inhibitors (BTK-inhibitors, such as ibrutinib and/or PI3-kinase inhibitors, such as idelalisib) Symptomatic disease requiring systemic therapy A Compassionate Access Program (CAP) approval is required prior to the initiation of treatment (please refer to https://cap.phsa.ca/).
AB	Funded	Jul 26, 2019	Venetoclax monotherapy for patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-cell receptor inhibitor (BCRi). Venetoclax monotherapy will also be available to patients who have an intolerance to ibrutinib. Treatment should be continued until disease progression or up to two years maximum.
SK	Funded	Sep 3, 2019	Monotherapy treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-cell receptor inhibitor (BCRi). Patients should have good performance status and treatment may be continued until disease progression or unacceptable toxicity.
MB	Funded	Aug 22, 2019	As monotherapy in patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-cell receptor inhibitor (BCRi) Patients should have good performance status and treatment should be continued until disease progression or unacceptable toxicity.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
ON	Under provincial consideration		
NS	Under provincial consideration		
NB	Under provincial consideration		
NL	Funded	Sep 10, 2019	As monotherapy for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who have received at least one prior therapy, and who have failed or are intolerant to a B-cell receptor inhibitor (BCRi). Patients must have a good performance status. Treatment should be discontinued upon disease progression or unacceptable toxicity.
PEI	Under provincial consideration		

Under provincial consideration means that the province is reviewing pCODR's recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.